JPRN-UMIN000003454已完成2 期
Phase II study of alternate-day administrations of S-1 as 2nd-line treatment in patients with metastatic and locally advanced pancreatic cancer - Phase II study of alternate-day administrations of S-1 as 2nd-line treatment in patients with metastatic and locally advanced pancreatic cancer
Pancreatic Cancer Treatment Research Group0 个研究点目标入组 45 人开始时间: 2010年4月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Symptomatic pulmonary fibrosis or interstitial pneumonia 2)Severe diarrhea 3)Active infection 4)Severe complications, such as ileus, heart failure and renal failure 5)Marked pleural or peritoneal effusion 6)Metastasis in central nervous system 7)Active double cancer 8)Patients under treatment with flucytosine, phenytoin or warfarin potassium 9)Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 10)Severe mental disorder 11)History of severe anaphylaxies 12)Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
已完成
2 期
Phase II Study of Alternate-day Administration of S-1 plus Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Canceron-small Cell Lung CancerJPRN-UMIN000012098Tokushukai Group Oncology Project45
已完成
2 期
Phase II Study of Alternate-day Administration of S-1 plus Carboplatin in Elderly Patients with Previously Treated Non-small Cell Lung CancerJPRN-UMIN000010989Tokushukai Group Oncology Project32
已完成
1 期
A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.colorectal cancerJPRN-UMIN000016094Aichi Cancer Center Hospital16
已完成
2 期
Phase II study of alternate-day administrations of S-1 as 1st-line treatment in patients with metastatic and locally advanced pancreatic cancerMetastatic or locally advanced pancreatic cancerJPRN-UMIN000003453Pancreatic Cancer Treatment Research Group45
已完成
2 期
A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer.Colorectal cancerJPRN-UMIN000020439Aichi Cancer Center Hospital25